Olopatadine 0.2%

DRUG2 trials

Sponsors

Senju USA, Inc., Allergan

Conditions

Allergic ConjunctivitisConjunctivitis, Allergic

Phase 2

Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

CompletedNCT00836485

Senju USA, Inc.Allergic Conjunctivitis

Start: 2009-02-28End: 2009-03-31Updated: 2023-08-04

Phase 4

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

CompletedNCT01732757

AllerganConjunctivitis, Allergic

Start: 2012-11-30End: 2012-12-31Updated: 2014-01-14